Avalo Therapeutics, Inc. (AVTX) stock
Close on Nov 11, 2026Market cap $456.39MP/E –Yield –
Avalo Therapeutics, Inc. saw revenue fall 86.6% to $59.00K over fiscal 2025. At the latest close the market valued the company at $456.39M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $456.39M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 1.05
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $59.00K
- Net income
- -$88.65M
- EPS, diluted
- -$2.90
- Book value per share
- $7.93
- Diluted shares
- 55M
Trading
- Next earnings
- Mar 22, 2027 (estimated, before the open)
- Previous close
- $7.16
- Open
- $7.24
- Day's range
- $7.17 – $8.55
- Volume
- 1,839,395
- Average volume (20 days)
- 3,238,556
- Index membership
- Russell 2000 (since Jun 2026), Russell 3000
- Beta (5 years)
- 0.88
- 52-week range
- $6.53 – $24.27
- RSI (14 days)
- 42.4
- Volatility (1 year)
- 91.1%
- Relative volume
- 1.27×
- WACC
- 9.3%
On 2 of our idea lists: More cash than they're worth, Institutions accumulating
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2015, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | AVTX | S&P 500 | Difference | AVTX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -37.7% | -2.4% | −35.2 pts | ||
| 3 months | -56.3% | -1.2% | −55.1 pts | ||
| Year to date | -53.1% | +12.3% | −65.4 pts | ||
| 1 year | -45.1% | +12.4% | −57.5 pts | ||
| 3 years | -60.7% | +78.8% | −139.6 pts | -26.8% | +21.4% |
| 5 years | -99.9% | +75.2% | −175.0 pts | -73.6% | +11.9% |
| 10 years | -99.9% | +311.1% | −411.0 pts | -52.0% | +15.2% |
Fourteen years at a glance
Fiscal years 2012 to 2025 and trailing twelve months, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Avalo Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Avalo Therapeutics Expands Pipeline with AVTX-010, a Long-Acting Next-Generation Anti-IL-1β AntibodyNews
- News
- Results
- News
About Avalo Therapeutics
Pharmaceutical Preparations
The company is a clinical-stage biotechnology firm that develops therapies targeting interleukin-1β for immune-mediated inflammatory diseases. Its primary product candidate is abdakibart, a humanized monoclonal antibody designed to block interleukin-1β and inhibit downstream inflammatory pathways. The candidate targets adults with moderate to severe hidradenitis suppurativa, a debilitating chronic skin condition. The firm also maintains legacy programs across other inflammatory and mitochondrial disorders. As its candidates remain in clinical evaluation without regulatory approvals, the company currently engages clinical study participants, with future customers comprising patients who suffer from underserved inflammatory diseases.
Company profile, executives and historyAvalo Therapeutics stock: common questions
What is Avalo Therapeutics's stock price?
AVTX closed at $8.51 on Nov 11, 2026, up 18.85% on the day. Over the past 52 weeks it traded between $6.53 and $24.27.
What is Avalo Therapeutics's market cap?
Avalo Therapeutics was worth $456.39M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is AVTX's P/E ratio?
Avalo Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$2.90), so it has no meaningful P/E ratio.
How much revenue does Avalo Therapeutics make?
Avalo Therapeutics reported revenue of $59.00K for fiscal 2025, down 86.6% from a year earlier.
Does Avalo Therapeutics pay a dividend?
No. Avalo Therapeutics has not paid a cash dividend over the last twelve months.
When does Avalo Therapeutics report earnings next?
Avalo Therapeutics is expected to report Q4 FY2026 results on Mar 22, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has AVTX stock performed over the past year?
Including dividends, AVTX returned -45.1% over the past year, against +12.4% for the S&P 500.
How many AVTX shares are sold short?
9M shares were sold short at the latest FINRA report, 16.73% of the float, or 2.1 days of average trading volume.
Who are Avalo Therapeutics's competitors?
Companies most similar to Avalo Therapeutics by business, industry and size include ALT, IXHL, IFRX, SILO, HIND.
See a number that looks wrong?